82 completed, 9 unknown, 8 terminated, 4 withdrawn. 109 Phase 1, 16 Phase 2.
Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department Rimegepant, Zavegepant - Migraine, Migraine Disease | Phase 1 | Recruiting | University of South Florida | 100 | 2026-09-15 | 2026-10-27 |
| A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults ODT2 Test formulation, ODT Reference formulation - Migraine | Phase 1 | Completed | Pfizer | 36 | 2026-05-11 | 2026-09-04 |
| Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura Fu's Subcutaneous Needling, Flunarizine Hydrochloride - Migraine Without Aura | Phase 1 | Not yet recruiting | Guangzhou University of Chinese Medicine | 60 | 2025-09-01 | 2025-07-16 |
| A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects PRT-064040 nasal spray, Placebo - Migraine | Phase 1 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 80 | 2025-06-07 | 2025-12-04 |
| A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine Zavegepant - Acute Treatment of Migraine | Phase 1 | Recruiting | Pfizer | 16 | 2025-05-16 | 2026-09-28 |
| A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine Ubrogepant, Lu AG09222, Placebo - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 43 | 2024-09-13 | 2025-10-14 |
| Self-acupuncture for Migraines Feasibility Study Acupuncture - Migraine | Phase 1 / Phase 2 | Enrolling by invitation | University of West London | 60 | 2024-09-13 | 2024-12-04 |
| Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1 Lidocaine hydrochloride, Methylprednisolone sodium succinate - Refractory Migraine | Phase 1 | Completed | The Cooper Health System | 10 | 2024-03-15 | 2025-11-04 |
| Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache Botox 200 UNT Injection, Non Botox based Standard of Care Treatments for Headache/Migraine - Stroke (CVA) or TIA, Headache, Migraine | Phase 1 | Withdrawn | University of Alberta | 2023-12-01 | 2024-09-19 | |
| Bioequivalence Study to Compare Ibuprofen/ Paracetamol Tablets (200mg Ibuprofen/ 500mg Paracetamol) Versus Nuromol® Tablets (200mg Ibuprofen/ 500mg Paracetamol) Ibuprofen/ Paracetamol tablets, Nuromol® tablets - Migraine, Headache | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2023-08-29 | 2023-12-22 |
| A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling Zavegepant 10 mg IN - Healthy | Phase 1 | Completed | Pfizer | 14 | 2023-07-10 | 2026-01-29 |
| A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects JS010 injection, Placebo - Migraine | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 48 | 2023-05-10 | 2026-07-17 |
| Sphenopalatine Ganglion Block Study Bupivacaine, angiocatheter - Sphenopalatine Ganglion Nerve Block | Phase 1 | Completed | Montefiore Medical Center | 220 | 2023-03-06 | 2024-10-08 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants UB-313, Placebo - Migraine | Phase 1 | Completed | Axxium Life, Inc. | 40 | 2022-07-06 | 2026-11-04 |
| A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants Lu AG09222, Placebo - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 52 | 2022-03-18 | 2022-11-10 |
| Study of Intravenous Erenumab in Patients With Status Migrainosus Erenumab - Status Migrainosus | Phase 1 | Withdrawn | Mayo Clinic | 2021-09-07 | 2022-02-22 | |
| Repeat Dosing of Psilocybin in Migraine Headache Psilocybin, Placebo - Migraine Headache | Phase 1 | Completed | Yale University | 18 | 2021-08-10 | 2024-02-09 |
| Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0 - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 48 | 2021-06-24 | 2021-09-17 |
| Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine Atogepant, Ubrogepant - Migraine | Phase 1 | Completed | AbbVie | 26 | 2021-03-17 | 2022-06-16 |
Showing 20 of 109. Sign in to see all of them.
Migraine Disorders (100) · Headache (11) · Cluster Headache (9) · Migraine with Aura (5) · Migraine without Aura (5) · Pain (3) · Anxiety Disorders (2) · Back Pain (2) · Epilepsy (2) · Fibromyalgia (2) · Headache Disorders (2) · Hypertension (2) · Acidosis, Lactic (1) · Asthma (1) · Blister (1)
Brain Diseases (109) · Central Nervous System Diseases (109) · Nervous System Diseases (109) · Headache Disorders (107) · Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (17) · Neurologic Manifestations (16) · Pain (11) · Trigeminal Autonomic Cephalalgias (8) · Cardiovascular Diseases (4) · Neuromuscular Diseases (4) · Vascular Diseases (4) · Musculoskeletal Diseases (3) · Skin and Connective Tissue Diseases (3)
Sumatriptan (9) · erenumab (6) · lasmiditan (6) · Topiramate (5) · Psilocybin (4) · zolmitriptan (4) · Botulinum Toxins, Type A (3) · Dexamethasone (3) · Dihydroergotamine (3) · eptinezumab (3) · galcanezumab (3) · ubrogepant (3) · AMG 333 (2) · Acupuncture Therapy (2) · Bupivacaine (2)
Eli Lilly and Company (8) · Amgen (7) · Pfizer (7) · Merck Sharp & Dohme LLC (6) · H. Lundbeck A/S (4) · GlaxoSmithKline (3) · Norwegian University of Science and Technology (3) · Yale University (3) · Zosano Pharma Corporation (3) · Acorda Therapeutics (2) · Alder Biopharmaceuticals, Inc. (2) · Danish Headache Center (2) · Mayo Clinic (2) · NuPathe Inc. (2) · Satsuma Pharmaceuticals, Inc. (2)
United States (61) · Belgium (7) · Canada (6) · Australia (4) · Denmark (4) · Brazil (3) · China (3) · Norway (3) · United Kingdom (2) · Germany (1) · Iran (1) · Japan (1) · Jordan (1) · Mexico (1) · Netherlands (1)
Don Kellerman, PharmD (2) · Adriana Conforto, MD,PHD (1) · Alex Rosin, MD (1) · Andrew Eisen, MD (1) · Anne Chiaramello, Ph.D. (1) · Athos Patsalides, MD, MPH (1) · Benjamin Friedman, MD (1) · Benoit Bailey, MD (1)
PMID 19461827, PMID 20637969, PMID 22289113, PMID 22305246, PMID 23369112, PMID 23798725, PMID 23975906, PMID 23992438, PMID 25164919, PMID 25168404, PMID 25297013, PMID 25500317, PMID 26232105, PMID 26381856, PMID 27154997, PMID 27910097, PMID 29765218, PMID 30152015, PMID 30232673, PMID 30617735, PMID 30659611, PMID 30963506, PMID 31482569, PMID 31852816, PMID 31985049, PMID 32583902, PMID 33184743, PMID 33565026, PMID 33781209, PMID 34823467, PMID 35594123, PMID 38413540, PMID 38581739, PMID 40444655, PMID 40530489, PMID 41459830, PMID 41608705, PMID 42012062
2014 (1), 2016 (1), 2019 (1), UH3TR003897 (1)